122 related articles for article (PubMed ID: 12559973)
1. Activation of cytochrome P450 2C9-mediated metabolism: mechanistic evidence in support of kinetic observations.
Hutzler JM; Wienkers LC; Wahlstrom JL; Carlson TJ; Tracy TS
Arch Biochem Biophys; 2003 Feb; 410(1):16-24. PubMed ID: 12559973
[TBL] [Abstract][Full Text] [Related]
2. Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
Hutzler JM; Hauer MJ; Tracy TS
Drug Metab Dispos; 2001 Jul; 29(7):1029-34. PubMed ID: 11408370
[TBL] [Abstract][Full Text] [Related]
3. Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: kinetics and structural requirements.
Hutzler JM; Kolwankar D; Hummel MA; Tracy TS
Drug Metab Dispos; 2002 Nov; 30(11):1194-200. PubMed ID: 12386124
[TBL] [Abstract][Full Text] [Related]
4. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
Hummel MA; Gannett PM; Aguilar JS; Tracy TS
Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
[TBL] [Abstract][Full Text] [Related]
5. Differential activation of CYP2C9 variants by dapsone.
Hummel MA; Dickmann LJ; Rettie AE; Haining RL; Tracy TS
Biochem Pharmacol; 2004 May; 67(10):1831-41. PubMed ID: 15130760
[TBL] [Abstract][Full Text] [Related]
6. The molecular basis of dapsone activation of CYP2C9-catalyzed nonsteroidal anti-inflammatory drug oxidation.
Nair PC; Burns K; Chau N; McKinnon RA; Miners JO
J Biol Chem; 2023 Dec; 299(12):105368. PubMed ID: 37866634
[TBL] [Abstract][Full Text] [Related]
7. CYP2D6-CYP2C9 protein-protein interactions and isoform-selective effects on substrate binding and catalysis.
Subramanian M; Low M; Locuson CW; Tracy TS
Drug Metab Dispos; 2009 Aug; 37(8):1682-9. PubMed ID: 19448135
[TBL] [Abstract][Full Text] [Related]
8. Minimal in vivo activation of CYP2C9-mediated flurbiprofen metabolism by dapsone.
Hutzler JM; Frye RF; Korzekwa KR; Branch RA; Huang SM; Tracy TS
Eur J Pharm Sci; 2001 Aug; 14(1):47-52. PubMed ID: 11457649
[TBL] [Abstract][Full Text] [Related]
9. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro.
Quintieri L; Bortolozzo S; Stragliotto S; Moro S; Pavanetto M; Nassi A; Palatini P; Floreani M
Drug Metab Pharmacokinet; 2010; 25(5):466-76. PubMed ID: 20877134
[TBL] [Abstract][Full Text] [Related]
10. Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen.
Tracy TS; Rosenbluth BW; Wrighton SA; Gonzalez FJ; Korzekwa KR
Biochem Pharmacol; 1995 May; 49(9):1269-75. PubMed ID: 7763308
[TBL] [Abstract][Full Text] [Related]
11. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9.
Tracy TS; Marra C; Wrighton SA; Gonzalez FJ; Korzekwa KR
Biochem Pharmacol; 1996 Oct; 52(8):1305-9. PubMed ID: 8937439
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 protein interactions with cytochrome b(5): effects on the coupling of catalysis.
Locuson CW; Wienkers LC; Jones JP; Tracy TS
Drug Metab Dispos; 2007 Jul; 35(7):1174-81. PubMed ID: 17446262
[TBL] [Abstract][Full Text] [Related]
13. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Korzekwa KR; Krishnamachary N; Shou M; Ogai A; Parise RA; Rettie AE; Gonzalez FJ; Tracy TS
Biochemistry; 1998 Mar; 37(12):4137-47. PubMed ID: 9521735
[TBL] [Abstract][Full Text] [Related]
15. CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone.
Winter HR; Wang Y; Unadkat JD
Drug Metab Dispos; 2000 Aug; 28(8):865-8. PubMed ID: 10901692
[TBL] [Abstract][Full Text] [Related]
16. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
17. Mechanism-based inactivation of cytochrome P450 2C9 by tienilic acid and (+/-)-suprofen: a comparison of kinetics and probe substrate selection.
Hutzler JM; Balogh LM; Zientek M; Kumar V; Tracy TS
Drug Metab Dispos; 2009 Jan; 37(1):59-65. PubMed ID: 18838506
[TBL] [Abstract][Full Text] [Related]
18. Substrate selectivity of human cytochrome P450 2C9: importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid.
Melet A; Assrir N; Jean P; Pilar Lopez-Garcia M; Marques-Soares C; Jaouen M; Dansette PM; Sari MA; Mansuy D
Arch Biochem Biophys; 2003 Jan; 409(1):80-91. PubMed ID: 12464247
[TBL] [Abstract][Full Text] [Related]
19. Use of simple docking methods to screen a virtual library for heteroactivators of cytochrome P450 2C9.
Locuson CW; Gannett PM; Ayscue R; Tracy TS
J Med Chem; 2007 Mar; 50(6):1158-65. PubMed ID: 17311370
[TBL] [Abstract][Full Text] [Related]
20. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
Mosher CM; Hummel MA; Tracy TS; Rettie AE
Biochemistry; 2008 Nov; 47(45):11725-34. PubMed ID: 18922023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
